1. A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells.
- Author
-
Rix, U., Rix, L. L. Remsing, Terker, A. S., Fernbach, N. V., Hantschel, O., Planyavsky, M., Breitwieser, F. P., Herrmann, H., Colinge, J., Bennett, K. L., Augustin, M., Till, J. H., Heinrich, M. C., Valent, P., Superti^Furga, G., and Remsing Rix, L L
- Subjects
CHRONIC myeloid leukemia ,PROTEIN-tyrosine kinase inhibitors ,PROTEOMICS ,IMATINIB ,OXIDOREDUCTASES ,CELL receptors ,CELLS ,COMPARATIVE studies ,HETEROCYCLIC compounds ,RESEARCH methodology ,MEDICAL cooperation ,PROTEIN kinases ,PROTEIN-tyrosine kinases ,PROTEINS ,RESEARCH ,TRANSFERASES ,EVALUATION research ,PROTEIN kinase inhibitors ,CHEMICAL inhibitors ,PHARMACODYNAMICS ,CELL physiology - Abstract
Resistance to the BCR-ABL tyrosine kinase inhibitor imatinib poses a pressing challenge in treating chronic myeloid leukemia (CML). This resistance is often caused by point mutations in the ABL kinase domain or by overexpression of LYN. The second-generation BCR-ABL inhibitor INNO-406 is known to inhibit most BCR-ABL mutants and LYN efficiently. Knowledge of its full target spectrum would provide the molecular basis for potential side effects or suggest novel therapeutic applications and possible combination therapies. We have performed an unbiased chemical proteomics native target profile of INNO-406 in CML cells combined with functional assays using 272 recombinant kinases thereby identifying several new INNO-406 targets. These include the kinases ZAK, DDR1/2 and various ephrin receptors. The oxidoreductase NQO2, inhibited by both imatinib and nilotinib, is not a relevant target of INNO-406. Overall, INNO-406 has an improved activity over imatinib but a slightly broader target profile than both imatinib and nilotinib. In contrast to dasatinib and bosutinib, INNO-406 does not inhibit all SRC kinases and most TEC family kinases and is therefore expected to elicit fewer side effects. Altogether, these properties may make INNO-406 a valuable component in the drug arsenal against CML. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF